Literature DB >> 32222733

All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma.

Maarten Haemels1, Sander Jentjens, Frederik Cleeren, Raf Sciot, Julie Lambert, Koen Van Laere, Karolien Goffin.   

Abstract

We present a case of a 79 year old patient with a medical history of unilateral nerve-sparing radical prostatectomy due to a pT3aN0 (Gleason score 7) prostate carcinoma. Because of slightly elevated prostate specific antigen (PSA) level (0.35ng/dL), a fluorine-18-prostate specific membrane antigen (18F-PSMA)-1007 positron emission tomography/computed tomography (PET/CT) scan was performed, showing no signs of malignant recurrence. However, a moderately PSMA-avid nodular lesion was observed in the left occipital region with homogeneous contrast enhancement, suggestive for a meningioma, which was confirmed on magnetic resonance imaging (MRI). One year later, the lesion was resected due to a small but significant growth. Histology confirmed the diagnosis of a transitional type meningioma (WHO grade 1).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32222733     DOI: 10.1967/s002449912007

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  3 in total

1.  [68 Ga]Ga-PSMA-11 Small Bowel Uptake in Crohn's Disease: Revisiting the "Non-specificity" of PSMA Ligands.

Authors:  Kunal Ramesh Chandekar; Sindhu Tanigassalam; Anwin Joseph Kavanal; Harmandeep Singh; Anish Bhattacharya; Ravimohan Suryanarayan Mavuduru
Journal:  Nucl Med Mol Imaging       Date:  2022-01-29

2.  Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma.

Authors:  Sowmya Veerasuri; Stewart Redman; Richard Graham; Chris Meehan; David Little
Journal:  BJR Case Rep       Date:  2020-11-03

Review 3.  Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.

Authors:  Brittany M Stopa; James Crowley; Csaba Juhász; Cara M Rogers; Mark R Witcher; Jackson W Kiser
Journal:  Mol Imaging       Date:  2022-04-15       Impact factor: 3.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.